Cointime

Transcept Pharmaceuticals

company

About

Transcept Pharmaceuticals focuses on the development of proprietary products that address therapeutic needs in the field of neuroscience.

  • 11 - 50

Highlights

Total Funding Amount
$40M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Series D
Last Funding Money Raised
$40M
Industries
Biotechnology,Neuroscience,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2001
Number Of Employee
11 - 50
Operating Status
Active

Transcept Pharmaceuticals, Inc. uses its proprietary delivery system to enhance the penetration of drugs, significantly speeding their onset of action. Transcept is developing rapid-acting versions of several major market pharmaceuticals. Hamilton co-invested in the company's first institutional round of funding alongside Montreaux Equity Partners, Peninsula Equity Partners and Vivo Ventures. Investors in subsequent financing rounds include these firms, and New Leaf Venture Partners, Interwest Partners and New Enterprise Associates.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$40M
Transcept Pharmaceuticals has raised a total of $40M in funding over 2 rounds. Their latest funding was raised on Mar 8, 2007 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 8, 2007 Series D $40M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
1
Transcept Pharmaceuticals is funded by 1 investors. Hercules Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Hercules Capital — Series D
Cointime
İçerikler
Şirket.